Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Broad, AstraZeneca Target Antibiotics

by Lisa M. Jarvis
September 17, 2012 | A version of this story appeared in Volume 90, Issue 38

AstraZeneca and the Broad Institute will work together to find new antibacterial and antiviral compounds. Under the two-year pact, Broad will screen its custom-made chemical library of 100,000 molecules generated by diversity-oriented synthesis. AstraZeneca will be responsible for optimizing and developing any lead compounds discovered by Broad. In the past 30 years, just two new classes of antibiotics have emerged, despite an alarming rise in drug-resistant bacteria, AstraZeneca notes.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.